Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Próba skuteczności chirurgicznej ablacji AF (SAFE)

2 października 2026 zaktualizowane przez: Richard Whitlock, Population Health Research Institute

SAFE is an international multicentre RCT of concomitant surgical atrial fibrillation (AF) ablation in patients with paroxysmal or persistent AF undergoing cardiac surgery.

Przegląd badań

Szczegółowy opis

Atrial fibrillation (AF) affects more than 1% of the general population and is an important risk factor for stroke. AF prevalence increases with age, occurring in 10 to 15% of patients older than 80 years of age, which is important with the aging population. Of patients undergoing cardiac surgery, 10.8% have a history of AF. AF is believed to cause the left atrium to dilate and lose its transport function. AF significantly increases the risk of ischemic stroke of cardioembolic origin, but is also associated with heart failure and impairs quality of life. Although the causal relationship between the 2 clinical entities has not been fully elucidated, AF is believed to cause heart failure via several mechanisms.

Ablation of AF is the application of scars to the atrial tissue to disrupt faulty electrical signals that cause the arrhythmia. If surgical ablation of AF yields a benefit similar to catheter-based AF ablation, thousands of people undergoing cardiac surgery could benefit from this procedure each year. SAFE will be a landmark trial in cardiac surgery, definitely establishing surgical AF ablation's impact on cardiovascular outcomes. Cardiac surgery is the optimal setting to establish whether maintenance of sinus rhythm through AF ablation yields clinical benefit, and is a setting where sham-control is possible. This will not only provide evidence for the cardiac surgical patients but will bolster the evidence for ablation (catheter or stand-alone surgical) in other AF patients.

The intervention under investigation is concomitant surgical AF ablation which is compared to no surgical AF ablation. The primary outcome is hospital readmissions with heart failure during 4 years of follow-up. This study will enroll 2000 patients from 50 centres, globally. Patients will be followed at hospital discharge, 4 to 6 weeks after surgery, 6 months after surgery, and then at 6-month intervals until the final follow-up visit, for a median follow-up for 4 years.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

2000

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Kopia zapasowa kontaktu do badania

Lokalizacje studiów

    • Ontario
      • Hamilton, Ontario, Kanada, L8L 2X2
        • Rekrutacyjny
        • Hamilton General Hospital
        • Kontakt:
        • Główny śledczy:
          • Richard Whitlock, MD MSc FRCSC

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Age ≥ 18 years;
  • Undergoing a clinically indicated cardiac surgical procedure: CABG, AVR, ascending aorta replacement, or combinations thereof;
  • Documented history of paroxysmal or persistent AF
  • Provide informed consent

Exclusion Criteria:

  • Dominant atrial arrhythmia is atrial flutter;

  • Documented left atrial diameter ≥ 6 cm;

  • Previous cardiac surgery requiring opening of the pericardium;

  • Patients undergoing any of the following procedures:

    1. Heart transplant
    2. Complex congenital heart surgery
    3. Sole indication for surgery is ventricular assist device insertion
    4. Mitral valve repair or replacement
    5. Tricuspid valve repair or replacement
  • Patient resides in a long-term care facility

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Zapobieganie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Poczwórny

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Surgical Atrial Fibrillation Ablation Group

Surgeon will perform left atrial ablation during patient's cardiac surgery procedure.

Surgeon will preform surgical atrial fibrillation ablation using either cryoablation or bipolar radiofrequency clamps including 2 layers of atrium or vein, a minimum of 2 burns per clamping with at least 3 lines in the ablation group. Cavo-tricuspid isthmus and mitral lines will be allowed.

Brak interwencji: No Surgical Atrial Fibrillation Ablation Group

Surgeon will not perform left atrial ablation during the patient's cardiac surgery procedure.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Number of hospital readmissions for heart failure over duration of follow-up
Ramy czasowe: Common termination point for trial (median follow-up of 4 years)

Total number of hospital readmissions for heart failure.

Common termination point for trial (median follow-up of 4 years)

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Number of Ischemic stroke or systemic arterial embolism events over duration of follow up
Ramy czasowe: Common termination point for trial (median follow-up of 4 years)

Number of Ischemic stroke or systemic arterial embolism events over duration of follow up

Common termination point for trial (median follow-up of 4 years)
Length of ICU stay
Ramy czasowe: From the date of study intervention surgery completion to the date of index hospital discharge, assessed up to the common termination point for trial (median follow-up of 4 years)

Length of ICU stay, including readmissions, from study intervention surgery to hospital discharge, including readmissions

From the date of study intervention surgery completion to the date of index hospital discharge, assessed up to the common termination point for trial (median follow-up of 4 years)
Length of hospital stay
Ramy czasowe: From the date of study intervention surgery completion to the date of index hospital discharge, assessed up to the common termination point for trial (median follow-up of 4 years)

Length of hospital stay

From the date of study intervention surgery completion to the date of index hospital discharge, assessed up to the common termination point for trial (median follow-up of 4 years)
Freedom from recurrence of atrial tachyarrhythmia
Ramy czasowe: 1 year post-operatively

Freedom from recurrence of atrial tachyarrhythmia

1 year post-operatively
Number of days free from admission to healthcare facility or presentation to the emergency department for heart failure
Ramy czasowe: Common termination point for trial (median follow-up of 4 years)

Number of days free admission to healthcare facility or presentation to the emergency department for heart failure

Common termination point for trial (median follow-up of 4 years)
All-cause mortality
Ramy czasowe: Common termination point for trial (median follow-up of 4 years)

All-cause mortality

Common termination point for trial (median follow-up of 4 years)
Cardiovascular mortality
Ramy czasowe: Common termination point for trial (median follow-up of 4 years)

Cardiovascular mortality

Common termination point for trial (median follow-up of 4 years)
Antiarrhythmic drug use
Ramy czasowe: Beyond 6 weeks until common termination point for trial (median follow-up of 4 years)

Antiarrhythmic drug use

Beyond 6 weeks until common termination point for trial (median follow-up of 4 years)
Number of patients undergoing atrial fibrillation ablation
Ramy czasowe: 90 days post- study surgery until common termination point for trial (median follow-up of 4 years)

Number of patients undergoing atrial fibrillation ablation

90 days post- study surgery until common termination point for trial (median follow-up of 4 years)
Quality of Life - atrial fibrillation specific
Ramy czasowe: At 1 year, and at common termination point for trial (median follow-up of 4 years)

Atrial fibrillation specific quality of life as assessed by the Atrial Fibrillation Effect on QualiTy of Life questionnaire (AFEQT) which is 20 questions using a 7 point Likert scale where a higher score means a worse outcome.

At 1 year, and at common termination point for trial (median follow-up of 4 years)
Quality of Life - heart failure specific
Ramy czasowe: At 1 year, and at common termination point for trial (median follow-up of 4 years)

Heart failure specific quality of life assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) which is a 12 questions using Likert scales where a higher score is a better outcome.

At 1 year, and at common termination point for trial (median follow-up of 4 years)
Quality of Life - General
Ramy czasowe: At 1 year, and at common termination point for trial (median follow-up of 4 years)

Quality of life- general as assessed by the European quality of life index version 5D (EQ-5D-5L) which consists of a descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement.

At 1 year, and at common termination point for trial (median follow-up of 4 years)

Inne miary wyników

Miara wyniku
Opis środka
Ramy czasowe
Number of Ischemic stroke and systemic arterial embolism
Ramy czasowe: Up to 30 days post-operatively

Safety outcome

Up to 30 days post-operatively
Number of patients requiring permanent pacemaker implantation
Ramy czasowe: Up to 1 year post-operatively

Safety outcome

Up to 1 year post-operatively
Volume of chest tube output
Ramy czasowe: Up to 24 hours post-operatively

Safety outcome - chest tube output measured in mL.

Up to 24 hours post-operatively
Re-operation for bleeding
Ramy czasowe: From date of study intervention surgery completion to date of index hospital discharge, assessed up to the common termination point for trial (median follow-up of 4 years)

Safety outcome

From date of study intervention surgery completion to date of index hospital discharge, assessed up to the common termination point for trial (median follow-up of 4 years)
All-cause mortality
Ramy czasowe: Prior to discharge or within 30 days post-operatively (whichever occurs first)

Safety outcome

Prior to discharge or within 30 days post-operatively (whichever occurs first)
Post-operative major bleeding
Ramy czasowe: <48 hours after surgery

Safety outcome

<48 hours after surgery
Number of patients with pulmonary vein stenosis
Ramy czasowe: At 1 year, and at common termination point for trial (median follow-up of 4 years)

Safety outcome

At 1 year, and at common termination point for trial (median follow-up of 4 years)
Number of patients with stiff left atrium syndrome
Ramy czasowe: At 1 year, and at common termination point for trial (median follow-up of 4 years)

Safety outcome

At 1 year, and at common termination point for trial (median follow-up of 4 years)
Number of patients with esophageal to atrial fistula
Ramy czasowe: At 1 year, and at common termination point for trial (median follow-up of 4 years)

Safety outcome

At 1 year, and at common termination point for trial (median follow-up of 4 years)
Health economic analysis of surgical atrial fibrillation
Ramy czasowe: At 1 year, and at common termination point (median follow-up of 4 years)

Economic analysis will be assessed via health care utilization by patients

At 1 year, and at common termination point (median follow-up of 4 years)
Health economic analysis of surgical atrial fibrillation
Ramy czasowe: At 1 year, and at common termination point (median follow-up of 4 years)

Economic analysis will be assessed via a questionnaire of health care visits and costs incurred by patients.

At 1 year, and at common termination point (median follow-up of 4 years)

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Główny śledczy: Richard Whitlock, Population Health Research Institute
  • Główny śledczy: Emilie Belley-Côté, Population Health Research Institute

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

1 czerwca 2023

Zakończenie podstawowe (Szacowany)

30 września 2027

Ukończenie studiów (Szacowany)

31 grudnia 2027

Daty rejestracji na studia

Pierwszy przesłany

4 maja 2022

Pierwszy przesłany, który spełnia kryteria kontroli jakości

22 czerwca 2022

Pierwszy wysłany (Rzeczywisty)

28 czerwca 2022

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

5 października 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

2 października 2026

Ostatnia weryfikacja

1 października 2026

Więcej informacji

Terminy związane z tym badaniem

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj